Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDLNASDAQ:CRMDNASDAQ:OCSNASDAQ:OVAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$9.13-1.0%$8.36$6.38▼$17.30$881.29M1.41.24 million shs1.46 million shsCRMDCorMedix$12.07-1.2%$9.29$3.61▼$13.85$823.40M1.541.17 million shs1.21 million shsOCSOculis$19.50$17.88$10.79▼$23.08$849.23M0.2744,224 shs39,563 shsOVASOvaScience$5.95-2.9%$12.74$0.66▼$1.52$213.19M3.11163,131 shs31,195 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%0.00%+6.04%+15.42%-41.44%CRMDCorMedix0.00%-2.35%+25.08%+16.51%+129.90%OCSOculis0.00%+2.58%+9.98%-0.41%+63.45%OVASOvaScience-2.94%-4.49%-16.32%+635.11%+85.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals2.2367 of 5 stars3.51.00.00.03.41.70.6CRMDCorMedix1.8232 of 5 stars3.61.00.00.03.40.00.6OCSOculis2.1485 of 5 stars3.53.00.00.02.70.00.6OVASOvaScienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.00Buy$19.43112.80% UpsideCRMDCorMedix 3.14Buy$15.0024.28% UpsideOCSOculis 3.00Buy$31.5061.54% UpsideOVASOvaScience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OVAS, AVDL, OCS, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.005/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.005/7/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.005/6/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/9/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/9/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/8/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.003/26/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$194.45M4.54N/AN/A$0.98 per share9.32CRMDCorMedix$82.55M9.92N/AN/A$1.28 per share9.43OCSOculis$980K868.78N/AN/A$2.87 per share6.79OVASOvaScience$290K735.13N/AN/A$1.80 per share3.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$0.27N/A152.17N/A-52.53%-93.34%-44.77%8/14/2025 (Estimated)CRMDCorMedix-$46.34M$0.22N/A12.84N/AN/A-79.21%-64.68%8/13/2025 (Estimated)OCSOculis-$98.92M-$2.64N/AN/AN/A-8,043.28%-71.31%-56.85%8/19/2025 (Estimated)OVASOvaScience-$50.97MN/A0.00∞N/A-10,128.37%-47.06%-42.39%N/ALatest OVAS, AVDL, OCS, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 million3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 million3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.972.60CRMDCorMedixN/A3.963.60OCSOculis0.014.024.02OVASOvaScienceN/A12.6212.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CRMDCorMedix34.18%OCSOculis22.30%OVASOvaScience22.52%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.80%CRMDCorMedix5.20%OCSOculisN/AOVASOvaScience7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7096.74 million91.74 millionOptionableCRMDCorMedix3067.83 million57.52 millionOptionableOCSOculis243.66 millionN/ANot OptionableOVASOvaScienceN/A35.83 millionN/ANot OptionableOVAS, AVDL, OCS, and CRMD HeadlinesRecent News About These CompaniesAssisted Reproductive Technology Market to Surpass USD 40.67 Billion by 2031 | SkyQuest TechnologyAugust 9, 2024 | finance.yahoo.comGlobal Fertility Services Market Report 2024-2032, by Cause of Infertility, Procedure, Service, End-User and RegionMay 21, 2024 | uk.finance.yahoo.comIn Vitro Fertilization Market Will Increase USD 40.6 Billion By 2032 With Around 7.8% CAGRApril 2, 2024 | pharmiweb.comInfertility Services Market Set for Remarkable Expansion, Worth USD 3.8 Billion by 2033 | Market.usMarch 13, 2024 | pharmiweb.comGeneral Catalyst Group V LP's Net WorthFebruary 11, 2024 | benzinga.comGlobal In Vitro Fertilization Market Size To Worth USD 39.12 Billion By 2032 | CAGR of 5.5%December 7, 2023 | finance.yahoo.comOvascience (OVAS) Stock Drops After Pricing Public OfferingNovember 4, 2023 | thestreet.comGlobal Retail Automation Market Size 2023-2027 | Drivers, Product Types, Applications, Growth Analysis and ForecastJune 30, 2023 | finance.yahoo.comTMRW Life Sciences Names Louis Villalba Chief Executive OfficerJune 27, 2023 | markets.businessinsider.comIVF Devices and Consumables Market Research Report 2023 Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2030June 22, 2023 | marketwatch.comOcuTerra Appoints Bill Steinkrauss as Chief Financial OfficerJune 1, 2023 | finance.yahoo.comIVF Market Business Approaches by 2030May 15, 2023 | marketwatch.comIVF Devices Market is Predicted to Reach US$ 6367 million by 2027 ... - StreetBuzzMay 14, 2023 | news.google.comSemen Analysis System Market SWOT analysis of key factors to ... - StreetBuzzMay 13, 2023 | news.google.comDonor Egg IVF Treatment Market Statistics, Share Price, Growth ... - Digital JournalMay 12, 2023 | news.google.comIVF Instruments Market Insights, Rising Trends and Global Demand ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comAssisted Reproductive Technologies (ART) Market Size Growth and ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comAssisted Reproductive Technology Market Expected to Reach USD 54.75 Billion by 2028 at a 9.7% CAGR - openPRMay 10, 2023 | news.google.comGlobal Assisted Reproductive Technology Market Global Segments ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comIn Vitro Fertilization Market is Expected to Reach USD 36.51 Billion ... - EIN NewsMay 9, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOVAS, AVDL, OCS, and CRMD Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$9.13 -0.09 (-0.98%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$9.08 -0.05 (-0.59%) As of 05/30/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.CorMedix NASDAQ:CRMD$12.07 -0.15 (-1.23%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$12.12 +0.04 (+0.37%) As of 05/30/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Oculis NASDAQ:OCS$19.42 -0.09 (-0.44%) As of 05/30/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.OvaScience NASDAQ:OVASMillendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
